{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:08:06Z","timestamp":1791612486724,"version":"4.3.4"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"DOI":"10.3389\/fcvm.2020.00088","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T01:12:39Z","timestamp":1589332359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":182,"title":["The Evolving Understanding and Approach to Residual Cardiovascular Risk Management"],"prefix":"10.3389","volume":"7","author":[{"given":"Devinder S.","family":"Dhindsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik B.","family":"Sandesara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0014-5793(01)02840-X","article-title":"Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages","volume":"505","author":"Carpenter","year":"2001","journal-title":"FEBS Lett."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0021-9150(00)00453-6","article-title":"Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL","volume":"151","author":"Hsieh","year":"2000","journal-title":"Atherosclerosis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1042\/bj3380479","article-title":"Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor","volume":"338","author":"Macphee","year":"1999","journal-title":"Biochem J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2006.05.001","article-title":"Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses","volume":"191","author":"Shi","year":"2007","journal-title":"Atherosclerosis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0021-9150(01)00674-8","article-title":"Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism","volume":"161","author":"Takahashi","year":"2002","journal-title":"Atherosclerosis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1161\/ATVBAHA.107.151670","article-title":"Prognostic utility of lipoprotein-associated phospholipase A for cardiovascular outcomes in patients with stable coronary artery disease","volume":"27","author":"Sabatine","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"STABILITY","year":"2014","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1373\/clinchem.2011.180281","article-title":"Relationship of lipoprotein-associated phospholipase A mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial","volume":"58","author":"Ridker","year":"2012","journal-title":"Clin Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2796.2010.02258.x","article-title":"Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality","volume":"268","author":"Group","year":"2010","journal-title":"J Intern Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2018","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019"},{"key":"B21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Eng J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1253\/circj.CJ-18-0871","article-title":"Clonal hematopoiesis and its impact on cardiovascular disease","volume":"83","author":"Sano","year":"2019","journal-title":"Circulation J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","article-title":"Clonal hematopoiesis. crossroads of aging, cardiovascular disease, and cancer: review topic of the week","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S0140-6736(17)30752-3","article-title":"Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study","volume":"389","author":"Kaplan","year":"2017","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1016\/j.jacc.2018.09.052","article-title":"Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome","volume":"72","author":"Gallone","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2011","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/eurheartj\/ehw627","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1172\/JCI117598","article-title":"Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma","volume":"94","author":"Steyrer","year":"1994","journal-title":"J Clin Investig"},{"key":"B39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","article-title":"New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease","volume":"27","author":"Tsimikas","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","article-title":"Lipoprotein Lp(a) and the risk for myocardial infarction","volume":"38","author":"Kostner","year":"1981","journal-title":"Atherosclerosis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.atherosclerosis.2018.06.895","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2017.07.024","article-title":"Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family","volume":"264","author":"Nikkola","year":"2017","journal-title":"Atherosclerosis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1194\/jlr.P091009","article-title":"A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population","volume":"60","author":"Liu","year":"2019","journal-title":"J Lipid Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"25709","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"2018","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","article-title":"Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"558","author":"Que","year":"2018","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vascular health and risk management"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/CIRCRESAHA.115.306398","article-title":"Surprises from genetic analyses of lipid risk factors for atherosclerosis","volume":"118","author":"Musunuru","year":"2016","journal-title":"Circul Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","article-title":"Extreme nonfasting remnant cholesterol vs. extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population","volume":"61","author":"Varbo","year":"2015","journal-title":"Clin Chem"},{"key":"B61","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem"},{"key":"B62","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-90-481-8622-8_8","article-title":"Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis","volume":"51","author":"Miller","year":"2010","journal-title":"Sub Cellular Biochem"},{"key":"B64","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0002-9149(96)00760-6","article-title":"Effect of a single high-fat meal on endothelial function in healthy subjects","volume":"79","author":"Vogel","year":"1997","journal-title":"Am J Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0021-9150(00)00499-8","article-title":"The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes","volume":"154","author":"Anderson","year":"2001","journal-title":"Atherosclerosis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/01.CIR.0000117403.64398.53","article-title":"Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol","volume":"109","author":"Shin","year":"2004","journal-title":"Circulation"},{"key":"B67","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000093221","article-title":"Effects of VLDL and remnant particles on platelets","volume":"35","author":"Olufadi","year":"2006","journal-title":"Pathophysiol Haemost Thromb"},{"key":"B68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Eng J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"Cd009580","DOI":"10.1002\/14651858.CD009580.pub2","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"2015","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/jama.256.20.2835","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"B79","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"B81","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.ATV.8.6.737","article-title":"High density lipoprotein cholesterol and mortality. The Framingham Heart Study","volume":"8","author":"Wilson","year":"1988","journal-title":"Arteriosclerosis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jvs.2017.11.029","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"B89","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART Study","volume":"68","author":"Ko","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1161\/ATVBAHA.118.311366","article-title":"Cholesterol mass efflux capacity, incident cardiovascular disease, and progression of carotid plaque","volume":"39","author":"Shea","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1194\/jlr.P069039","article-title":"HDL efflux capacity, HDL particle size, and high-risk carotid atherosclerosis in a cohort of asymptomatic older adults: the Chicago Healthy Aging Study","volume":"58","author":"Mutharasan","year":"2017","journal-title":"J Lipid Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/13543784.2018.1543399","article-title":"CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction","volume":"27","author":"Capodanno","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diabetes Vasc Dis Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study?","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"B106","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e1001971","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catala-Lopez","year":"2016","journal-title":"PLoS Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc20-S010","volume":"43","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2020.00088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T01:12:44Z","timestamp":1589332364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2020.00088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":111,"alternative-id":["10.3389\/fcvm.2020.00088"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2020.00088","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"article-number":"88"}}